Skip to main content

Glatiramer use while Breastfeeding

Medically reviewed by Last updated on Jun 15, 2023.

Drugs containing Glatiramer: Copaxone, Glatopa

Glatiramer Levels and Effects while Breastfeeding

Summary of Use during Lactation

Glatiramer is the active portion of the drug, glatiramer acetate. The drug is undetectable in most women and appears in only low amounts for up to 3 hours in others. Furthermore, the oral absorption by the breastfed infant is estimated to be less than 3%, except perhaps in neonates.[1] Follow-up of infants indicates that maternal use of glatiramer acetate does not appear to cause any adverse effects in breastfed infants. Glatiramer acetate is generally considered safe by most experts and appears to be one of the preferred disease-modifying agents for treating multiple sclerosis during breastfeeding.[2-9] No special precautions appear to be required during breastfeeding while using glatiramer and breastfeeding can resume immediately after injection.[10]

Drug Levels

Maternal Levels. In a manufacturer-sponsored study, healthy volunteers were given 60 mg of glatiramer acetate subcutaneously. Milk samples were obtained at 5, 15, 30, 60, 120, 240, and 360 minutes after injection. Glatiramer was detectable in the milk of 9 of 17 subjects, and undetectable (<50 mcg/L) in the others. It was detectable for up to 30 minutes in 8 subjects and up to 360 minutes in one other. The authors estimated that in the worst-case scenario, an exclusively breastfed infant would receive a relative infant dose of 9% of the maternal weight-adjusted dosage in milk. However the infant would be systemically exposed to a maximum of only 0.2% of the mother’s dose when the poor oral bioavailability is considered.[1]

Seventeen healthy volunteers were given a 60 mg subcutaneous injection of iodine125-labeled glatiramer acetate. Glatiramer was undetectable (<50 mcg/L) in eight subjects by one hour after the injection. Assuming that milk levels were equal to peak serum levels and a low oral bioavailability, the authors estimated the relative infant dose to be 0.2%.[11]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Nine mothers received glatiramer acetate (dosage not stated) during pregnancy and postpartum for multiple sclerosis and breastfed their infants for an average of 3.6 months (range 1 to 12 months). No infections, signs of inadequate digestion or other important ill effects were reported in their breastfed infants during the neonatal period. Follow-up of the infants at 1 year or longer found no neurological or developmental deficits in the infants except for one otherwise normal infant with delayed language development who had been breastfed for 3 months.[7]

Three mothers received glatiramer acetate (dosage not stated) for multiple sclerosis during pregnancy and postpartum. All of their infants were exclusively breastfed for 6 months and no noticeable problems were reported in any of them.[12]

In data collected from 4 countries, 41 women received glatiramer acetate and 17 women received interferon during pregnancy and postpartum for treatment of multiple sclerosis. Of these, 63% breastfed (extent not stated) their infants for a mean of 8.8 months. No mention was made of adverse reactions in breastfed infants.[13]

Among 1182 live birth pregnancies in the manufacturer’s pharmacovigilance database, breastfeeding was reported for 14.3% of women (n = 169). During the first month after birth breastfeeding was reported in 10 mothers using 20 mg/mL daily and 64 using the 40 mg/mL three times weekly dosage regimen. Follow-up questionnaires were sent to patients or their healthcare providers at 1 and 12 months postpartum. Among 40 women who completed the 12-month questionnaires, 3 received the 20 mg/mL dose, 36 received the 40 mg/mL dose, and 1 received both doses. Of 27 women with known breastfeeding practices, exclusive breastfeeding for 4 or more months was reported for 17 (63.0%) respondents. Partial breastfeeding, defined as breastfeeding for less than 4 months or mixed breast and bottle feeding, was reported for ten (37.0%) mothers. The mean duration of exposure while breastfeeding was 7 months (SD = 4.3 months) with durations up to 13 months. Of 40 breastfeeding women, infant characteristics at birth and at approximately 12 months of age were available for 18 breastfed infants, all to the 40 mg/mL dose. The mean infant weight and length at birth and 12 months were within the normal range for the World Health Organization z-score and percentiles.[14]

In a retrospective, non-interventional, study from the German Multiple Sclerosis & Pregnancy Registry , 60 infants breastfed by mothers with multiple sclerosis treated with glatiramer were compared to 60 breastfed infants of mothers with MS not treated with a disease-modifying therapy. The median duration of breastfeeding during glatiramer use was 7 months (range 0.2 to 19.1 months). No difference was found in the number of hospitalizations for infection between the two groups up to 18 months of age. No differences in weight, length, or head circumference were seen between infants in the two cohorts up to 12 months of age.[8] A follow-up analysis found no difference in the number or types of serious adverse effects in infants between the two groups.[9]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Immune Globulin, Interferon Beta, Methylprednisolone


Ashkenazi N, Hallak H. Evaluation of the potential newborn exposure to glatiramer acetate (Copaxone) via lactation. Eur J Neurol 2022;29:467. [Abstract]. doi: 10.1111/ene.15466. [CrossRef]
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol. 2014;124:1157–68. [PubMed: 25415167]
Fragoso YD. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: A safety evaluation. Expert Opin Drug Saf. 2014;13:1743–8. [PubMed: 25176273]
Thöne J, Thiel S, Gold R, et al. Treatment of multiple sclerosis during pregnancy - safety considerations. Expert Opin Drug Saf. 2017;16:523–34. [PubMed: 28333552]
Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19:106–14. [PubMed: 30612100]
Dobson R, Hellwig K. Use of disease-modifying drugs during pregnancy and breastfeeding. Curr Opin Neurol. 2021;34:303–11. [PubMed: 33709977]
Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series. CNS Drugs. 2010;24:969–76. [PubMed: 20806993]
Ciplea AI, Kurzeja A, Thiel S, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study. Mult Scler. 2022;28:1641–50. [PMC free article: PMC9315183] [PubMed: 35362346]
Ciplea AI, Kurzeja A, Thiel S, et al. Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis. Mult Scler Relat Disord. 2023;75:104771. [PubMed: 37245349]
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
Ashkenazi N, Hallak H. Evaluation of the use of glatiramer acetate during breast feeding. Int J Toxicol 2023;42:87. [Abstract]. doi: 10.1177/10915818221143638. [CrossRef]
Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258:502–3. [PubMed: 20878174]
Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115:154–9. [PubMed: 22633835]
Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. Drug Saf. 2022;45:345–57. [PubMed: 35297004]

Substance Identification

Substance Name


CAS Registry Number

28704-27-0 147245-92-9

Drug Class

Breast Feeding


Milk, Human

Immunologic Adjuvants

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.